Visualizing cellularity and angiogenesis in newly-diagnosed glioblastoma with diffusion and perfusion MRI and FET-PET imaging.
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
16 Aug 2021
16 Aug 2021
Historique:
received:
11
06
2021
accepted:
28
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
Combining imaging modalities has become an essential tool for assessment of tumor biology in glioblastoma (GBM) patients. Aim of this study is to understand how tumor cellularity and neovascularization are reflected in O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography ([18F] FET PET) and magnetic resonance imaging (MRI) parameters, including cerebral blood volume (CBV), fractional anisotropy (FA) and mean diffusivity (MD). In this prospective cohort, 162 targeted biopsies of 43 patients with therapy-naïve, isocitrate dehydrogenase (IDH) wildtype GBM were obtained after defining areas of interest based on imaging parameters [18F] FET PET, CBV, FA and MD. Histopathological analysis of cellularity and neovascularization was conducted and results correlated to imaging data. ANOVA analysis showed a significant increase of CBV in areas with high neovascularization. For diffusion metrics, and in particular FA, a trend for inverse association with neovascularization was found. [18F] FET PET showed a significant positive correlation to cellularity, while CBV also showed a trend towards correlation with cellularity, not reaching significant levels. In contrast, MD and FA were negatively associated with cellularity. Our study confirms that amino acid PET and MR imaging parameters are indicative of histological tumor properties in glioblastoma and highlights the ability of multimodal imaging to assess tumor biology non-invasively.
Identifiants
pubmed: 34398358
doi: 10.1186/s13550-021-00817-3
pii: 10.1186/s13550-021-00817-3
pmc: PMC8368421
doi:
Types de publication
Journal Article
Langues
eng
Pagination
72Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 824
Informations de copyright
© 2021. The Author(s).
Références
J Neurooncol. 2008 Jun;88(2):205-10
pubmed: 18317691
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1468-1475
pubmed: 31953672
Radiology. 2006 Sep;240(3):803-10
pubmed: 16926329
Nucl Med Biol. 2006 Apr;33(3):287-94
pubmed: 16631076
Neuro Oncol. 2011 Mar;13(3):307-16
pubmed: 21292686
J Neuroradiol. 2019 Feb;46(1):44-51
pubmed: 29753641
Cancer Imaging. 2014 Nov 14;14:31
pubmed: 25608485
Brain Pathol. 2005 Oct;15(4):297-310
pubmed: 16389942
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
Cancers (Basel). 2021 Jan 19;13(2):
pubmed: 33478030
AJNR Am J Neuroradiol. 2011 Oct;32(9):1646-51
pubmed: 21835939
Contrast Media Mol Imaging. 2018 Dec 2;2018:6828396
pubmed: 30627060
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2163-2168
pubmed: 31289907
J Nucl Med. 1999 Aug;40(8):1367-73
pubmed: 10450690
Magn Reson Imaging. 2016 May;34(4):410-21
pubmed: 26708034
AJNR Am J Neuroradiol. 2008 Mar;29(3):476-82
pubmed: 18079184
Front Neuroinform. 2014 Feb 21;8:8
pubmed: 24600385
NMR Biomed. 2002 Nov-Dec;15(7-8):543-52
pubmed: 12489100
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931